Developing improvements in cannabidiol and other cannabinoids from C. sativa, and a computational analysis of the interaction between the cannabinoids and relevant receptors

点击翻译按钮获取中文摘要

With the legalization of cannabis in Canada, we expect to see an increase in overt recreational use. However,**THC, the psychoactive cannabinoid is one of only 113 known cannabinoids produced by C. sativa. Preliminary**research has shown that the other cannabinoids, although lacking any psychoactive activity, might have**potentially potent biomedical applications, including for anti-cancer, anti-inflammatory, and local analgesic**activity. They could provide a starting point for developing new classes of therapies from readily available**materials. However, several problems must be addressed before we can advance the field. We need an easily**scalable, simple, and inexpensive method to isolate cannabidiol (CBD) from crude plant extracts in high purity**and yield. We also need an improved understanding of the affinity of CBD and other minor cannabinoids for the**various receptors on cell surfaces as the profile of these interactions determines the physiological effects. This**collaboration between the University of Windsor and Aphria, a leading grower of medical cannabis, seeks to**address both of these issues.